Zealand Pharma wants to buy access to the US market through bankrupt firm Zealand Pharma's bid on bankrupt medtech company Valeritas is an attempt to buy a shortcut into the US market by taking over a fully functional commercial organization in the country. Emmanuel Dulac, CEO of Zealand Pharma Photo: Zealand Pharma/ PR BY KEVIN GRØNNEMANN Published: 13.02.20 at 05:51 Share by email Share on LinkedIn Share on Facebook Share on Twitter Log in to read our articles Welcome to MedWatch. A part of our content is exclusive and reserved for our users. Log in Try MedWatch for 14 days. Get a trial subscription here. Do you want a trial subscription with multiple users for yourself and your colleagues? Read more about your options and find the contact information to our sales team here. Print Print Increase text size Increase text size Decrease text size Decrease text size Related articles Novo Ventures invests millions in Zealand competitor after initiative organized by Zealand co-founder Share issue gives Orphazyme breakthrough with US investors Zealand's Dutch leading investor looks forward to two hectic years: "There are multiple triggers"